The benign prostatic hyperplasic devices market in South & Central America is expected to grow from US$ 146.38 million in 2022 to US$ 218.16 million by 2028; it is estimated to grow at a CAGR of 6.9% from 2022 to 2028.
Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate. BPH is a non-cancerous prostate condition that is not usually fatal. Being benign, the condition does not involve metastasis to other body parts. BPH is not associated with the risk of prostate cancer; moreover, unless it manifests symptoms, BPH isn’t considered a health issue. Almost all men are likely to have some prostate growth by the time they turn 70. Aging, abdominal obesity, and lack of physical exercise raise the risk of developing BPH. According to the National Center for Biotechnology Information (NCBI), BPH is one of the most common disorders in older men and the leading cause of lower urinary tract symptoms (LUTS). After the age of 40, the prevalence of BPH rises, reaching a peak of 60% by the age of 90. According to autopsy studies, the histological prevalence of BPH is 8%, 50%, and 80% in the fourth, sixth, and ninth decades of the life of a man, respectively. According to statistics from the Krimpen and Baltimore Longitudinal Study of Aging, the prostate grows at a rate of 2.0% to 2.5% per year in older men. Continued prostate enlargement is a risk factor for developing LUTS, and larger prostates are associated with a benign prostatic enlargement (BPE), which triggers the risk of developing clinical BPH and urine incontinence. According to NCBI data, increased adiposity is found to have a positive correlation with prostate volume. In numerous study groups, body weight, body mass index (BMI), and waist circumference have been seen to have a positive correlation with prostate volume. Additionally, epidemiological data shows obesity may raise the necessity of BPH surgery and initiating BPH treatment. The treatment option for BPH includes surgeries such as transurethral resection of the prostate (TURP), open prostatectomy, and minimally invasive treatments such as transurethral needle ablation (TUNA). In minimally invasive treatments such as radiofrequency ablation, laser therapy, and implants, benign prostatic hyperplasic devices are used. Thus, the increase in the prevalence of benign prostatic hyperplasia and increasing risk factors can bolster the demand for benign prostatic hyperplasic devices.
South & Central America Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
South & Central America Benign Prostatic Hyperplasic Devices Market Segmentation
The South & Central America benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period. Based on procedure type, the South & Central America benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period. Based on end user, the South & Central America benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period. Based on country, the South & Central America benign prostatic hyperplasic devices market is segmented into Brazil, Argentina, and Rest of SAM. In 2022, Brazil held a larger market share. On the other side, and the same segment is expected to register a higher CAGR during the forecast period.
KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the South & Central America benign prostatic hyperplasic devices market.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South & Central America Benign Prostatic Hyperplasic Devices Market – By Product
1.3.2 South & Central America Benign Prostatic Hyperplasic Devices Market – By Procedure Type
1.3.3 South & Central America Benign Prostatic Hyperplasic Devices Market – By End User
1.3.4 South & Central America Benign Prostatic Hyperplasic Devices Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Benign Prostatic Hyperplasic Devices – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. South & Central America Benign Prostatic Hyperplasic Devices Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Boosting Prevalence of Benign Prostatic Hyperplasia along with Growing Risk Factors
5.1.2 Increasing Investments, Funds, and Grants for Research in BPH Treatment
5.1 Market Restraints
5.1.1 Lesser Awareness of Prostate Health Among Men
5.2 Market Opportunities
5.2.1 Emerging Markets
5.3 Future Trends
5.3.1 Growing Product Approvals and Launches
5.4 Impact Analysis
6. South & Central America Benign Prostatic Hyperplasic Devices Market Analysis
6.1 South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Forecast and Analysis
7. South & Central America Benign Prostatic Hyperplasic Devices Market – by Product
7.1 South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Product (2022 and 2028)
7.2 Resectoscopes
7.2.1 Overview
7.2.2 Resectoscopes: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.3 Urology Lasers
7.3.1 Overview
7.3.2 Urology Lasers: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Radiofrequency Ablation Devices
7.4.1 Overview
7.4.2 Radiofrequency Ablation Devices: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Prostatic Stents
7.5.1 Overview
7.5.2 Prostatic Stents: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Implants
7.6.1 Overview
7.6.2 Implants: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8. South & Central America Benign Prostatic Hyperplasic Devices Market – by Procedure Type
8.1 South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Procedure Type (2022 and 2028)
8.2 Transurethral Microwave Therapy
8.2.1 Overview
8.2.2 Transurethral Microwave Therapy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Transurethral Resection of the Prostate
8.3.1 Overview
8.3.2 Transurethral Resection of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Transurethral Needle Ablation of the Prostate
8.4.1 Overview
8.4.2 Transurethral Needle Ablation of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Laser Surgery
8.5.1 Overview
8.5.2 Laser Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.6 UroLift Surgery
8.6.1 Overview
8.6.2 UroLift Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
9. South & Central America Benign Prostatic Hyperplasic Devices Market – by End User
9.1 Overview
9.2 South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Share, by End User (2022 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Ambulatory Surgical Centers
9.5.1 Overview
9.5.2 Ambulatory Surgical Centers Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
10. South & Central America Benign Prostatic Hyperplasic Devices Market – by Country Analysis
10.1 Overview
10.1.1 South & Central America: Benign Prostatic Hyperplasic Devices Market, by Country, 2022 & 2028 (%)
10.1.1.1 Brazil: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Brazil: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 Brazil: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Product (US$ Million)
10.1.1.1.4 Brazil: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast To 2028, By Procedure Type (US$ Million)
10.1.1.1.5 Brazil: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2 Argentina Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Argentina Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 Argentina: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Product (US$ Million)
10.1.1.2.4 Argentina: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast To 2028, By Procedure Type (US$ Million)
10.1.1.2.5 Argentina: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3 Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market– Revenue and Forecast to 2028 (USD Mn)
10.1.1.3.1 Overview
10.1.1.3.2 Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market– Revenue and Forecast to 2028 (USD Mn)
10.1.1.3.3 Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Product (US$ Million)
10.1.1.3.4 Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast To 2028, By Procedure Type (US$ Million)
10.1.1.3.5 Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
11. South & Central America Benign Prostatic Hyperplasic Devices Market – Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.3 Organic Growth Strategies
12. Company Profiles
12.1 KARL STORZ SE & Co. KG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Richard Wolf GmbH
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Olympus Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Boston Scientific Corporation
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Teleflex Incorporated
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms for South & Central America Benign Prostatic Hyperplasia Devices Market
LIST OF TABLES
Table 1. Brazil: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Product (US$ Million)
Table 2. Brazil: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Procedure Type (US$ Million)
Table 3. Brazil: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 4. Argentina: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Product (US$ Million)
Table 5. Argentina: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Procedure Type (US$ Million)
Table 6. Argentina: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Product (US$ Million)
Table 8. Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028, By Procedure Type (US$ Million)
Table 9. Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 10. Recent Inorganic Growth Strategies in the Benign Prostatic Hyperplasia Devices Market
Table 11. Recent Organic Growth Strategies in the Benign Prostatic Hyperplasia Devices Market
Table 12. Glossary of Terms
LIST OF FIGURES
Figure 1. South & Central America Benign Prostatic Hyperplasic Devices Market Segmentation
Figure 2. South & Central America Benign Prostatic Hyperplasic Devices Market, By Country
Figure 3. South & Central America Benign Prostatic Hyperplasic Devices Market Overview
Figure 4. Resectoscopes Segment Held Largest Share of Product Segment in Benign Prostatic Hyperplasic Devices Market
Figure 5. Brazil is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. South & Central America Benign Prostatic Hyperplasic Devices Market, Industry Landscape
Figure 7. South And Central America: PEST Analysis
Figure 8. Experts Opinion
Figure 9. South & Central America Benign Prostatic Hyperplasic Devices Market – Revenue Forecast and Analysis – 2020-2028
Figure 10. South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Product (2022 and 2028)
Figure 11. Resectoscopes: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Urology Lasers: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Radiofrequency Ablation Devices: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Prostatic Stents: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Implants: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Share, by Procedure Type (2022 and 2028)
Figure 17. Transurethral Microwave Therapy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Transurethral Resection of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Transurethral Needle Ablation of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Laser Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. UroLift Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Share, by End User (2022 and 2028)
Figure 24. Hospitals Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. Clinics Market Revenue and Forecast to 2028 (US$ Million)
Figure 26. Ambulatory Surgical Centers Market Revenue and Forecast to 2028 (US$ Million)
Figure 27. Others Market Revenue and Forecast to 2028 (US$ Million)
Figure 28. South & Central America Benign Prostatic Hyperplasic Devices Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 29. South & Central America: Benign Prostatic Hyperplasic Devices Market, by Country, 2022 & 2028 (%)
Figure 30. Brazil: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
Figure 31. Argentina Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
Figure 32. Rest of South & Central America: Benign Prostatic Hyperplasic Devices Market– Revenue and Forecast to 2028 (USD Mn)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America benign prostatic hyperplasic devices market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the South & Central America benign prostatic hyperplasic devices market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the benign prostatic hyperplasic devices market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The List of Companies – South & Central America Benign Prostatic Hyperplasic Devices Market
● KARL STORZ SE & Co. KG
● Olympus Corporation
● Boston Scientific Corporation
● Teleflex Incorporated
● Richard Wolf GmbH
At 6.9% CAGR, the South & Central America Benign Prostatic Hyperplasic Devices Market is speculated to be worth US$ 218.16 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the South & Central America benign prostatic hyperplasic devices market was valued at US$ 146.38 million in 2022 and is expected to reach US$ 218.16 million by 2028, registering an annual growth rate of 6.1% from 2022 to 2028. Growing product approvals and launches and boosting prevalence of BPH among men along with increasing.
Leading players in the benign prostatic hyperplasic devices market focus on expanding their customer reach across emerging markets by expanding their distribution networks and augmenting manufacturing capabilities. In addition, high investments in life science and healthcare research in emerging countries play a crucial role in the upgrading of the latest technologies in developing countries. In turn, this supports the inclination toward advanced benign prostatic hyperplasia treatments. Crucial benign prostatic hyperplasic device manufacturers in Brazil are expected to witness lucrative opportunities in the future owing to the large patient pool and high benign prostatic hyperplasia prevalence, increasing disposable income, improving healthcare infrastructure, and growing medical tourism in countries across the region.
On the contrary, lesser awareness about prostate health among men.
Based on product, the South & Central America benign prostatic hyperplasic devices market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment held 34.8% market share in 2022, amassing US$ 50.94 million. It is projected to garner US$ 75.13 million by 2028 to expand at 6.7% CAGR during 2022–2028. Based on procedure type, the South & Central America benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held 28.4% market share in 2022, amassing US$ 41.53 million. It is projected to garner US$ 63.95 million by 2028 to expand at 7.5% CAGR during 2022–2028. Based on end user, the South & Central America benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 41.9% market share in 2022, amassing US$ 61.38 million. It is projected to garner US$ 90.58 million by 2028 to expand at 6.7% CAGR during 2022–2028 Based on country, the South & Central America benign prostatic hyperplasic devices market has been segmented into Brazil, Argentina, and Rest of SAM. Our regional analysis states that Brazil captured 58.8% market share in 2022. It was assessed at US$ 86.05 million in 2022 and is likely to hit US$ 131.15 million by 2028, exhibiting a CAGR of 7.3% during the forecast period. Key players dominating the South & Central America benign prostatic hyperplasic devices market are KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH among others.
In June 2021, Olympus Corporation acquired Israeli medical device company Medi-Tate Ltd. Through this acquisition, Olympus expanded its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidified its position as a leader in the field of urological devices. In September 2021, Olympus was selected to exhibit the iTind device, a temporarily implanted device for the relief of enlarged prostate symptoms, at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange virtually from September 21-23.
We provide our clients with insightful market research reports and competitive intelligence that helps them stay ahead of the curve.
Business-era specializes in accelerating growth and providing improved brand value to organizations in the competitive market. We synergize with organizations to connect clients and businesses.